Literature DB >> 10531121

Immunosuppression in renal transplantation. Meta-analysis should not have included one of the studies.

G Morris-Stiff, A Khan, I Quiroga, R Baboo, W A Jurewicz.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10531121      PMCID： PMC1116919     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

Review 1.  Immunosuppressive strategies in transplantation.

Authors:  M D Denton; C C Magee; M H Sayegh
Journal:  Lancet       Date:  1999-03-27       Impact factor: 79.321

2.  FK 506 in clinical kidney transplantation.

Authors:  R Shapiro; M Jordan; V Scantlebury; J Fung; C Jensen; A Tzakis; J McCauley; P Carroll; C Ricordi; A J Demetris
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506.

Authors:  A J Krentz; J Dmitrewski; D Mayer; P McMaster; J Buckels; B Dousset; R Cramb; J M Smith; M Nattrass
Journal:  Transplantation       Date:  1994-06-15       Impact factor: 4.939

4.  Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation.

Authors:  G Morris-Stiff; T Richards; J Singh; K Baboolal; V Balaji; K Ostrowski; R Moore; C Darby; R Lord; W A Jurewicz
Journal:  Transplant Proc       Date:  1998-06       Impact factor: 1.066

5.  Acute rejection following renal transplantation. Evidence that severity is the best predictor of subsequent graft survival time.

Authors:  R P Pelletier; F Cosio; M L Henry; G L Bumgardner; E A Davies; E A Elkhammas; R M Ferguson
Journal:  Clin Transplant       Date:  1998-12       Impact factor: 2.863

6.  Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression.

Authors:  D F Mirza; B K Gunson; Z Soonawalla; J Pirenne; A D Mayer; J A Buckels; P McMaster
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

7.  Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials.

Authors:  G A Knoll; R C Bell
Journal:  BMJ       Date:  1999-04-24

8.  Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.

Authors:  S G Pollard; P A Lear; A R Ready; R H Moore; R W Johnson
Journal:  Transplantation       Date:  1999-11-15       Impact factor: 4.939

9.  Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.

Authors:  M G Otto; A D Mayer; P A Clavien; A Cavallari; K A Gunawardena; E A Mueller
Journal:  Transplantation       Date:  1998-12-27       Impact factor: 4.939

10.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359
  10 in total
  2 in total

1.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 2.  Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

Authors:  C J Dunn; A J Wagstaff; C M Perry; G L Plosker; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.